BVXV - BiondVax Pharmaceuticals Ltd.
| Previous Close | 5.25 |
| Open | 5.12 |
| Bid | 4.96 x 800 |
| Ask | 11.80 x 2200 |
| Day's Range | 5.05 - 5.24 |
| 52 Week Range | 4.64 - 7.71 |
| Volume | 6,744 |
| Avg. Volume | 4,136 |
| Market Cap | 33.403M |
| Beta (3Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.00 |
- GlobeNewswire•20 days ago
Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•22 days ago
BiondVax CEO to Present at 'World Vaccine Congress 2018 San Diego' About BiondVax's Phase 3 Universal Flu Vaccine Candidate
JERUSALEM, Nov. 26, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present this week at the World Vaccine & Immunotherapy Congress West Coast 2018 in San Diego. Dr. Ron Babecoff, BiondVax's Founder and CEO, will participate in a panel discussion and provide an overview of the Company's achievements and plans, including the ongoing pivotal, clinical efficacy, Phase 3 trial. Panel: How will we integrate knowledge gained from the UIVI and other research into the development of a Universal Influenza Vaccine?
- Zacks Small Cap Research•28 days ago
BVXV: Enrollment of First Season Cohort Complete in Phase 3 Trial of Universal Influenza Vaccine…
BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial is being conducted in Europe following feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).
- PR Newswire•29 days ago
BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
JERUSALEM , Nov. 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- PR Newswire•last month
BiondVax Announces Third Quarter 2018 Financial Results
JERUSALEM , Nov. 13, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- PR Newswire•2 months ago
BiondVax's Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season's Enrollment of 4,098 Participants
The 4,098 participants enrolled in this year's cohort will be monitored for two flu seasons. A second cohort of approximately 6,000 participants will be enrolled prior to the 2019/2020 flu season. Safety, as well as laboratory confirmed influenza incidence will be assessed, with results expected in the second half of 2020.
- PR Newswire•2 months ago
BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial
JERUSALEM, Oct. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of an €8 million disbursement from the European Investment Bank (EIB). The first two tranches totaling €12 million were received by BiondVax earlier this year.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks Small Cap Research•3 months ago
BVXV: Phase 3 Trial of M-001 Underway…
BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to conduct it from the European Medicines Agency (EMA).
- PR Newswire•3 months ago
BiondVax to Present at Influenza 2018 Oxford Conference
JERUSALEM, Sept. 4, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today it will present at the Influenza 2018 Oxford conference at the University of Oxford. Joshua Phillipson, BiondVax's Business Development Manager, will provide an overview of the Company's clinical development achievements and plans, including the recently launched pivotal, clinical efficacy, Phase 3 trial.
- PR Newswire•4 months ago
BiondVax Announces Second Quarter 2018 Financial Results
JERUSALEM , Aug. 22, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- PR Newswire•4 months ago
BiondVax Moves to New Universal Flu Vaccine Manufacturing Facility
JERUSALEM, Aug. 20, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of the M-001 universal influenza vaccine candidate, reported today the company's relocation to a newly constructed mid-size commercial scale manufacturing facility in Jerusalem, Israel. Dr. Shimon Hassin, BiondVax's COO, commented, "BiondVax's new facility is custom-built for GMP manufacturing of our innovative flu vaccine candidate, which can be produced year-round and is designed to provide broad protection against influenza.
- PR Newswire•4 months ago
BiondVax Receives Second €6M Tranche Disbursement From the European Investment Bank (EIB)
NESS ZIONA, Israel, Aug. 14, 2018 /PRNewswire/ --- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase 3 Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). The first tranche of €6 million was received by BiondVax in June 2018[2]. Funds will be advanced in three tranches.
- PR Newswire•4 months ago
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
The primary endpoints of the trial are to demonstrate protection from influenza and safety of M-001. A secondary endpoint will assess reduction in flu illness severity among those receiving M-001 versus placebo. In six completed clinical trials in Israel and Europe (two Phase 1/2 and four Phase 2), M-001 has been shown to be safe, well-tolerated, and immunogenic to a broad range of influenza strains.
- PR Newswire•6 months ago
Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
NESS ZIONA, Israel, June 28, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain as Vice-Chairman of its Board of Directors. Based in New York, and having served as founder, director, chairman of the board, and/or investor in over twenty biotech companies, and with experience assisting in arranging corporate partnerships, acquiring technology, entering mergers and acquisitions, and executing financings, Mr. Germain is well suited to help guide BiondVax's ongoing corporate development. Mr. Mark Germain commented, "I am pleased and excited to join the BiondVax board at this important time in the development of the company.
- PR Newswire•6 months ago
BiondVax Receives Its First €6M Tranche Disbursement From the European Investment Bank (EIB)
NESS ZIONA, Israel, June 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (BVXV), developer of M‑001, a clinical phase Universal Influenza Vaccine candidate, announced today the receipt of a €6 million disbursement from the European Investment Bank (EIB). Dr. Ron Babecoff, BiondVax's President and CEO, commented, "We plan to begin our first pivotal, clinical efficacy, Phase 3 trial later this year, while the construction of our mid-size commercial manufacturing facility is well underway. "We are grateful for the excellent ongoing collaboration and relationship with the EIB towards the development of our universal flu vaccine," continued Babecoff.
- Zacks Small Cap Research•7 months ago
BVXV: Increased Media Coverage for M-001 Ahead of Phase 3 Clinical Trial
BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).
- PR Newswire•7 months ago
BiondVax Announces First Quarter 2018 Financial Results
NESS ZIONA, Israel , May 29, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu ...
- Zacks Small Cap Research•7 months ago
BVXV: Set to Initiate Phase 3 Clinical Trial of Universal Influenza Vaccine Candidate in 2H18
BiondVax Pharmaceuticals,Ltd. (BVXV) is a biopharmaceutical company developing a universal influenza vaccine (M-001) designed to protect individuals from all strains of influenza. The company’s strategy for commercializing M-001 involves testing it in a pivotal Phase 3 program as a standalone influenza vaccine to assess its clinical efficacy. The first Phase 3 trial will be conducted in Europe and the company has received feedback about the trial design and approval to initiate it from the European Medicines Agency (EMA).
- PR Newswire•8 months ago
BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update
NESS ZIONA, Israel , April 30, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal ...
- ACCESSWIRE•8 months ago
Blog Exposure - BiondVax Pharma Initiated NIH-Sponsored Phase-2 Clinical Trial of M-001 in the US
Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...
- PR Newswire•8 months ago
BiondVax to Present at Universal Influenza Vaccines Conference
NESS ZIONA, Israel , April 12, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal ...
- PR Newswire•8 months ago
BiondVax Begins NIH-Sponsored Phase 2 Clinical Trial of Its Universal Flu Vaccine in the United States
NESS ZIONA, Israel , April 11, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) reported today the first participant enrollment in the United States in a Phase 2 clinical trial of the ...